• Pharming Group flagged new clinical readouts for leniolisib, with interim pediatric APDS outcomes slated for presentation at Clinical Immunology Society (CIS) 2026 in New Orleans during May 6-9.
• Disclosures will cover long-term extension experience in children ages 4-11, with updates focused on how patients are doing on treatment rather than new dosing or regimen changes.
• Separate CIS posters will outline real-world expanded-access use of leniolisib in CVID and CVID-like disorders, aimed at supporting broader development beyond APDS.
• Two ongoing phase 2 trials are evaluating leniolisib safety and tolerability in CVID and other primary immunodeficiencies with immune dysregulation, with results expected in second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.